MAGEA12: A Potential Drug Target and Biomarker for Cancer and Testis Antigens

Target Name: MAGEA12

NCBI ID: G4111

MAGEA12

MAGEA12: A Potential Drug Target and Biomarker for Cancer and Testis Antigens

Introduction

Cancer is a leading cause of death worldwide, with over 20% of the global population affected. One of the major challenges in cancer treatment is the development of resistance to drugs, leading to a poor prognosis for patients. To address this issue, there is a growing interest in identifying new biomarkers and drug targets for cancer. In this article, we discuss MAGEA12, a cancer/testis antigen 1.12, as a potential drug target and biomarker.

MAGEA12: Structure and Function

MAGEA12 is a 12-kDa glycoprotein that is expressed in various tissues, including cancer cells, testes, and placenta. It is a member of the MAGEA family, which includes MAGEA1, MAGEA3, MAGEA9, and MAGEA12. MAGEA12 is composed of a variable region (VR) and a constant region (CR). The VR includes a N-terminal region with a putative transmembrane anchoring domain and a C-terminal region that contains a unique glycosylation site. The CR includes a N-terminal region with a putative transmembrane anchoring domain and a C-terminal region that contains a glycosylation site.

MAGEA12 has been shown to play a critical role in cancer progression and metastasis. It has been shown to be involved in the development of various types of cancer, including breast, ovarian, and prostate cancer. MAGEA12 has also been shown to be involved in the development of metastasis, as it has been shown to be expressed in various tissues that have been implicated in metastasis, including the lungs, liver, and brain.

Drug Target Potential

MAGEA12 has been identified as a potential drug target due to its unique structure and function. One of the key features of MAGEA12 is its transmembrane nature, which suggests that it may be a good target for small molecules. Additionally, MAGEA12 has been shown to play a role in cell signaling, as it is involved in the PI3K/Akt signaling pathway. This suggests that MAGEA12 may be a good target for inhibitors of this pathway.

Biomarker Potential

MAGEA12 has also been shown to be a potential biomarker for cancer. Its expression has been shown to be associated with various types of cancer, including breast, ovarian, and prostate cancer. Additionally, MAGEA12 has been shown to be involved in the development of metastasis , which suggests that it may be a good biomarker for monitoring the effectiveness of cancer treatments.

Conclusion

MAGEA12 is a promising cancer/testis antigen 1.12 that has the potential to be a drug target and biomarker. Its transmembrane nature and involvement in cell signaling make it a promising target for small molecules. Additionally, its association with various types of cancer and its potential as a biomarker for cancer make it a promising candidate for further research.

Overall, MAGEA12 is a potential drug target and biomarker for cancer that deserves further investigation. Further studies are needed to determine its effectiveness and its potential as a drug.

Protein Name: MAGE Family Member A12

Functions: Not known, though may play a role tumor transformation or progression. In vitro promotes cell viability in melanoma cell lines

The "MAGEA12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGEA12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets